{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:43:10Z","timestamp":1780990990270,"version":"3.54.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":910,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The prevalence of advanced heart failure (HF) is increasing due to the growing number of patients with HF and their better treatment and survival. There is a scarcity of data on the accuracy of HF web-based risk scores in this selected population.<\/jats:p>\n                    <jats:p>This study aimed to assess mortality prediction performance of the Meta-Analysis Global Group in Chronic HF (MAGGIC-HF) risk score and the model of the Barcelona Bio-HF Risk Calculator (BCN-Bio-HF) containing N terminal pro brain natriuretic peptide in HF patients receiving intermittent inotropic support with levosimendan as destination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Four hundred and three advanced HF patients from 23 tertiary hospitals in Spain receiving intermittent inotropic support with levosimendan as destination therapy were included. Discrimination for all-cause mortality was compared by area under the curve (AUC) and Harrell's C-statistic at 1 year. Calibration was assessed by calibration plots comparing observed versus expected events based on estimated risk by each calculator. The included patients were predominantly men, aged 71.5 [interquartile range 64\u201378] years, with reduced left ventricular ejection fraction (27.5 \u00b1 9.4%); ischaemic heart disease was the most prevalent aetiology (52.5%). Death rate at 1 year was 26.8%, while the predicted 1-year mortality by BCN-Bio-HF and MAGGIC-HF was 17.0% and 22.1%, respectively. BCN-Bio-HF AUC was 0.66 (Harrell's C-statistic 0.64), and MAGGIC-HF AUC was 0.62 (Harrell's C-statistic 0.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The two evaluated risk scores showed suboptimal discrimination and calibration with an underestimation of risk in advanced HF patients receiving levosimendan as destination therapy. There is a need for specific scores for advanced HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14400","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T06:45:22Z","timestamp":1688798722000},"page":"2875-2881","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Heart Failure Risk Scores in Advanced Heart Failure Patients: Insights from the LEVO-D Registry"],"prefix":"10.1093","volume":"10","author":[{"given":"Pau","family":"Codina","sequence":"first","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol , Badalona ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Autonoma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dobarro","sequence":"additional","affiliation":[{"name":"Hospital \u00c1lvaro Cunqueiro. Complexo Hospitalario Universitario de Vigo , Vigo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier de","family":"Juan-Bagud\u00e1","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12) , Madrid ,","place":["Spain"]},{"name":"Department of Medicine, Faculty of Biomedical and Health Science, Universidad Europea de Madrid , Madrid ,","place":["Spain"]},{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"De Frutos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari de Bellvitge, BIOHEART-Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Lup\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol , Badalona ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Autonoma de Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol , Badalona ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Autonoma de Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Gonzalez-Costello","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital Universitari de Bellvitge, BIOHEART-Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona ,","place":["Spain"]},{"name":"Department of Clinical Sciences, School of Medicine, Universitat de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Spanish LEVO-D registry Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"key":"2026012113211179000_ehf214400-bib-0001","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"2026012113211179000_ehf214400-bib-0003","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1002\/ehf2.13670","article-title":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study","volume":"8","author":"Garc\u00eda-Gonz\u00e1lez","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0004","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0005","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial","volume":"16","author":"Altenberger","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0006","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ehf2.14278","article-title":"Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: the LEVO-D registry","volume":"10","author":"Dobarro","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0007","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ehf2.12366","article-title":"Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period","volume":"6","author":"P\u00f6lzl","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1751-7133.2011.00241.x","article-title":"Multivariate risk scores and patient outcomes in advanced heart failure","volume":"17","author":"Ketchum","year":"2011","journal-title":"Congest Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0009","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/ejhf.2352","article-title":"Head-to-head comparison of contemporary heart failure risk scores","volume":"23","author":"Codina","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0010","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012113211179000_ehf214400-bib-0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085466","article-title":"Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN bio-HF calculator)","volume":"9","author":"Lup\u00f3n","year":"2014","journal-title":"PLoS ONE"},{"key":"2026012113211179000_ehf214400-bib-0012","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ejhf.2752","article-title":"Barcelona bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment","volume":"25","author":"Codina","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0013","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.949","article-title":"Barcelona bio-HF calculator version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization","volume":"20","author":"Lup\u00f3n","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0014","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jacc.2008.10.023","article-title":"Utility of the Seattle heart failure model in patients with advanced heart failure","volume":"53","author":"Kalogeropoulos","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012113211179000_ehf214400-bib-0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/CIRCHEARTFAILURE.110.944280","article-title":"Application of the Seattle heart failure model in ambulatory patients presented to an advanced heart failure therapeutics committee","volume":"3","author":"Gorodeski","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0016","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003745","article-title":"Accuracy of Seattle heart failure model and HeartMate II risk score in non-inotrope-dependent advanced heart failure patients: insights from the ROADMAP study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients)","volume":"10","author":"Lanfear","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026012113211179000_ehf214400-bib-0017","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113211179000_ehf214400-bib-0018","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113211179000_ehf214400-bib-0019","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jjcc.2013.01.015","article-title":"Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function","volume":"61","author":"Horii","year":"2013","journal-title":"J Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/2875\/66227799\/eschf_10_5_2875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/2875\/66227799\/eschf_10_5_2875.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:26:03Z","timestamp":1769019963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/5\/2875\/8284392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,8]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14400","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"2023-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}